|
1
|
Pontoni G, Ferrari S, Gabbieri D, Pedulli
M, Gambetti D, Ghidoni I and Rigatelli M: FC28-04 - Quality of life
assessment after cardiac surgery in octogenarians: Is it really
feasible? Eur Psychiatry. 26:19742011.http://www.em-consulte.com/article/289736/fc28-04-quality-of-life-assessment-after-cardiac-s
View Article : Google Scholar
|
|
2
|
Massé L and Antonacci M: Low cardiac
output syndrome: Identification and management. Crit Care Nurs Clin
North Am. 17:375–383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Algarni KD, Maganti M and Yau TM:
Predictors of low cardiac output syndrome after isolated coronary
artery bypass surgery: Trends over 20 years. Ann Thorac Surg.
92:1678–1684. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mangano DT, Hollenberg M, Fegert G, Meyer
ML, London MJ, Tubau JF and Krupski WC: The Study of Perioperative
Ischemia (SPI) Research Group: Perioperative myocardial ischemia in
patients undergoing noncardiac surgery - I: Incidence and severity
during the 4 day perioperative period. J Am Coll Cardiol.
17:843–850. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He XM, Chen L, Luo JB, Feng XX, Zhang YB,
Chen QJ, Ji XL and Wang TS: Effects of rhBNP after PCI on
non-invasivehemodynamic in acute myocardial infarction patients
with left heart failure. Asian Pac J Trop Med. 9:791–795. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Targońska S, Kozioł MM, Czajkowski M,
Stążka J and Kozioł-Montewka M: Sternal wound complications after
cardiac surgery - a case report. Wiad Lek. 68:95–98. 2015.(In
Polish). PubMed/NCBI
|
|
7
|
Kerneis CK, Lafarge AL, Larnier LL,
Scalbert F, Brusset AB, Estagnasie PE and Squara PS: Bowel and
related complications after cardiac surgery. Crit Care. 19 Suppl
1:P3752015. View
Article : Google Scholar
|
|
8
|
Howell NJ, Ashrafian H, Drury NE,
Ranasinghe AM, Contractor H, Isackson H, Calvert M, Williams LK,
Freemantle N, Quinn DW, et al: Glucose-insulin-potassium reduces
the incidence of low cardiac output episodes after aortic valve
replacement for aortic stenosis in patients with left ventricular
hypertrophy: Results from the Hypertrophy, Insulin, Glucose, and
Electrolytes (HINGE) trial. Circulation. 123:170–177. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Howard BT, Iles TL, Coles JA, Sigg DC and
Iaizzo PA: Reversible and irreversible damage of the myocardium:
Ischemia/reperfusion injury and cardioprotectionHandbook of Cardiac
Anatomy, Physiology, and Devices. 3rd edition. Springer
International Publishing; New York: 2015, View Article : Google Scholar
|
|
10
|
Madamanchi C, Alhosaini H, Sumida A and
Runge MS: Obesity and natriuretic peptides, BNP and NT-proBNP:
Mechanisms and diagnostic implications for heart failure. Int J
Cardiol. 176:611–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oremus M, Don-Wauchope A, McKelvie R,
Santaguida PL, Hill S, Balion C, Booth R, Brown JA, Ali U, Bustamam
A, et al: BNP and NT-proBNP as prognostic markers in persons with
chronic stable heart failure. Heart Fail Rev. 19:471–505. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boer BP, Vieira ML, Sampaio RO, Abensur H,
Oliveira AG, Fernandes JR and Grinberg M: Correlation to NT-ProBNP
and remodeling after cardiac surgery. Arq Bras Cardiol.
100:469–475. 2013.PubMed/NCBI
|
|
13
|
Recombinant Human Brain Natriuretic
Peptide Multicenter Clinical Study Group, . Hu DY: Efficacy and
safety of intravenous recombinant human brain natriuretic peptide
in patients with decompensated acute heart failure: A multicenter,
randomized, open label, controlled study. Zhonghua Xin Xue Guan
Bing Za Zhi. 39:305–308. 2011.(In Chinese). PubMed/NCBI
|
|
14
|
Xing K, Fu X, Wang Y, Li W, Gu X, Hao G,
Miao Q, Li S, Jiang Y, Fan W, et al: Effect of rhBNP on renal
function in STEMI-HF patients with mild renal insufficiency
undergoing primary PCI. Heart Vessels. 31:490–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S and Wang Z: Effect of recombinant
human brain natriuretic peptide (rhBNP) versus nitroglycerin in
patients with heart failure: A systematic review and meta-analysis.
Medicine (Baltimore). 95:e47572016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu XQ, Hong HS, Lin XH, Chen LL and Li
YH: Changes in cardiac aldosterone and its synthase in rats with
chronic heart failure: an intervention study of long-term treatment
with recombinant human brain natriuretic peptide. Braz J Med Biol
Res. 47:646–654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Zhang L, Wu Q, Liu H and Huang L:
Recombinant human brain natriuretic peptide therapy combined with
bone mesenchymal stem cell transplantation for treating heart
failure in rats. Mol Med Rep. 7:628–632. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bakkehaug JP, Kildal AB, Engstad ET,
Boardman N, Næsheim T, Rønning L, Aasum E, Larsen TS, Myrmel T and
How OJ: Response to letter regarding article, ‘Myosin activator
omecamtiv mecarbil increases myocardial oxygen consumption and
impairs cardiac efficiency mediated by resting myosin ATPase
activity’. Circ Heart Fail. 8:11422015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lyu T, Zhao Y, Zhang T, Zhou W, Yang F, Ge
H, Ding S, Pu J and He B: Natriuretic peptides as an adjunctive
treatment for acute myocardial infarction: Insights from the
meta-analysis of 1,389 patients from 20 trials. Int Heart J.
55:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
